Last reviewed 2026-04-23 · How we verify

ASC22

ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells.

ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells. Used for Non-small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC).

At a glance

Mechanism of action

ASC22 targets programmed death ligand 1 (PD-L1), a key immune checkpoint protein expressed on tumor cells and immune cells. By blocking PD-L1 interactions with its receptors (PD-1 and B7.1), the drug relieves immune suppression in the tumor microenvironment, allowing T cells to recognize and attack cancer cells more effectively. This mechanism is designed to restore anti-tumor immunity in patients with PD-L1-expressing malignancies.

Approved indications

• Non-small cell lung cancer (NSCLC)
• Hepatocellular carcinoma (HCC)

Common side effects

• Fatigue
• Decreased appetite
• Nausea
• Immune-related adverse events (irAEs)

Key clinical trials

• A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients (PHASE2)
• Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV (PHASE2)
• Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ASC22 CI brief — competitive landscape report
• ASC22 updates RSS · CI watch RSS
• Ascletis Pharmaceuticals Co., Ltd. portfolio CI